In vitro simulation study of individualized chemotherapy in lung cancer

Journal of Nippon Medical School

Volumn 74, Issue 3, 2007, Pages 217-222

  Li, Cai ^a   Gemma, Akihiko ^a   Minegishi, Yuji ^a   Matsuda, Kuniko ^a   Seike, Yoko ^a   Noro, Rintaro ^a   Shionoya, Aki ^b   Kawakami, Akiko ^b   Ogawa, Naoki ^b   Kudoh, Shoji ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b Genetic Lab Co Ltd   (Japan)

Author keywords

cDNA array; Cell lines; Lung cancer; Taylor made chemotherapy

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; GLUTATHIONE TRANSFERASE P1; IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; NAVELBINE; URIDINE PHOSPHORYLASE;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; HUMAN; LUNG CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL LINE, TUMOR; CISPLATIN; DEOXYCYTIDINE; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; TAXOIDS; VINBLASTINE;

EID: 34347354130     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.74.217     Document Type: Article

References (18)

1. Murray N, Livingston RB, Shepherd FA, et al.: Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999; 17: 2300-2308.
2. Ayash LJ, Elias A, Wheeler C, et al.: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37-44.
3. Fukuoka M, Furuse K, Saijo N, et al.: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83: 855-861.
4. Roth BJ, Johnson DH, Einhorn LH, et al.: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 282-291.
5. Salmon SE: Human tumor colony assay and chemosensitivity testing. Cancer Treat Rep 1984; 68: 117-125.
6. Bogden AE, Von Hoff DD: Comparison of the human tumor cloning and subrenal capsule assays. Cancer Res 1984; 44: 1087-1090.
7. Schiller JH, Harrington D, Belani CP, et al.; Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
8. Bonomi P, Kim K, Fairclough D, et al.: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18: 623-631.
9. Alberola V, Camps C, Provencio M, et al.; Spanish Lung Cancer Group: Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21: 3207-3213.
10. Alberola V, Camps C, Provencio M, et al.; Spanish Lung Cancer Group: Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21: 3207-3213.
11. Miller VA, Johnson DH, Krug LM, et al.: Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol 2003; 21: 2094-2100.
12. Georgoulias V, Papadakis E, Alexopoulos A, et al.; Greek Oncology Cooperative Group (GOCG) for Lung Cancer: Greek Oncology Cooperative Group (GOCG) for Lung Cancer. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001; 357: 1478-1484.
13. Shepherd FA, Dancey J, Ramlau R, et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
14. Gemma A, Li C, Sugiyama Y, Matsuda K, et al.: Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database. BMC Cancer 2006; 6: 174.
15. Gemma A, Takenaka K, Hosoya Y, et al.: Altered expression of several genes in highly metastatic subpopulations of a human pulmonary adenocarcinoma cell line. Eur J Cancer 2001; 37: 1554-1561.
16. Olaussen KA, Dunant A, Fouret P, et al.; IALT Bio Investigators: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991.
17. Okamoto R, Takano H, Okamura T, et al.: O (6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives. Jpn J Cancer Res 2002; 93: 93-102.
18. Adams DJ, Knick VC: P-glycoprotein mediated resistance to 5′-nor-anhydro-vinblastine (Navelbine). Invest New Drugs 1995; 13: 13-21.